Skip to main content

Advertisement

SpringerLink
Log in

Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

We aim to examine the characteristics and survival of patients with de novo metastatic breast cancer (dnMBC) and recurrent metastatic breast cancer (rMBC) in New Zealand.

Methods

This study included women diagnosed with dnMBC and women who developed rMBC between 2010 and 2017. The Kaplan–Meier method was used to examine cancer-specific survival. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) of cancer-specific mortality by ethnicity, age, year of diagnosis, socioeconomic deprivation, site of metastases, number of metastatic sites, biomarker subtype and MBC subgroup.

Results

We included 2177 MBC patients (667 dnMBC and 1510 rMBC). The median survival of dn MBC patients was 26 months compared to 18 months for rMBC. There were no differences in breast-cancer specific mortality by ethnicity or socioeconomic deprivation. The adjusted HR for patients with visceral metastases compared to patients with non-visceral metastases was 1.41, and the adjusted HR for triple negative disease compared to Luminal A disease was 2.24. Compared to dnMBC, the adjusted HRs for rMBC patients with a metastatic-free interval of < 2 years, 2–4 years, 5–7 year and 8 + years were 1.81, 1.47, 1.08 and 0.82, respectively.

Conclusions

The survival for patients with MBC in New Zealand is very similar to other developed countries. Patients with dnMBC had a much better prognosis than those with recurrent disease. Patients with triple negative disease or non-luminal HER2 positive disease had the worst prognosis. The prognosis for patient with rMBC improved the longer the time from diagnosis to the development of metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I. Stage of breast cancer at diagnosis in New Zealand: Impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016. https://doi.org/10.1186/s12885-016-2177-5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0.

    Article  Google Scholar 

  3. Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller DP. Comparing survival after recurrent vs De Novo Stage IV advanced breast, lung, and colorectal cancer. JNCI Cancer Spectrum. 2018;2(2):pky024. https://doi.org/10.1093/jncics/pky024.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Malmgren JA, Mayer M, Atwood MK, Kaplan HG. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat. 2018;167(2):579–90. https://doi.org/10.1007/s10549-017-4529-5.

    Article  PubMed  Google Scholar 

  5. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445–511. https://doi.org/10.1038/bjc.2015.127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol: Off J Eur Soc Med Oncol. 2010;21(11):2169–74. https://doi.org/10.1093/annonc/mdq220.

    Article  CAS  Google Scholar 

  7. Yamamura J, Kamigaki S, Fujita J, Osato H, Komoike Y. The difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2 − negative breast cancer. Vivo. 2018;32(2):353–8. https://doi.org/10.21873/invivo.11245.

    Article  Google Scholar 

  8. New Zealand Breast Cancer Foundation. Insights into living—and dying—with Advanced Breast Cancer in New Zealand. New Zealand: Auckland; 2018.

    Google Scholar 

  9. den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549–56. https://doi.org/10.1007/s10549-016-4080-9.

    Article  Google Scholar 

  10. Zeichner SB, Ambros T, Zaravinos J, Montero AJ, Mahtani RL, Ahn ER, Mani A, Markward NJ, Vogel CL. Defining the survival benchmark for breast cancer patients with systemic relapse. Breast Cancer: Basic Clin Res. 2015;9:9–17. https://doi.org/10.4137/bcbcr.s23794.

    Article  Google Scholar 

  11. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59(3):271–8. https://doi.org/10.1023/a:1006308619659.

    Article  CAS  PubMed  Google Scholar 

  12. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091. https://doi.org/10.1186/s12885-019-6311-z.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;97(3):545–53. https://doi.org/10.1002/cncr.11083.

    Article  PubMed  Google Scholar 

  14. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M (2018) American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. Radiographics: a review publication of the Radiological Society of North America, Inc 38(7):1921–1933. https://doi.org/10.1148/rg.2018180056

  15. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol: Off J Eur Soc Med Oncol. 2015;26(8):1533–46. https://doi.org/10.1093/annonc/mdv221.

    Article  CAS  Google Scholar 

  16. Lawrenson R, Lao C, Campbell I, Harvey V, Seneviratne S, Elwood M, Sarfati D, Kuper-Hommel M. The impact of different tumour subtypes on management and survival of New Zealand women with Stage I–III breast cancer. N Z Med J. 2018;131(1475):51–60.

    PubMed  Google Scholar 

  17. Lawrenson R, Lao C, Campbell I, Harvey V, Seneviratne S, Edwards M, Elwood M, Scott N, Kidd J, Sarfati D, Kuper-Hommel M. Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes. Cancer Causes Control: CCC. 2017;28(12):1417–27. https://doi.org/10.1007/s10552-017-0969-9.

    Article  PubMed  Google Scholar 

  18. Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M. The use of trastuzumab in New Zealand women with breast cancer. Asia-Pacific J Clin Oncol. 2017. https://doi.org/10.1111/ajco.12766.

    Article  Google Scholar 

  19. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. https://doi.org/10.1200/jco.2013.50.9984.

    Article  Google Scholar 

  20. Thuerlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St Gallen, Switzerland. Breast Cancer (Tokyo, Japan). 2001;8(4):294–7.

    Article  CAS  Google Scholar 

  21. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin Ke (2015) SEER Cancer Statistics Review, 1975–2012. National Cancer Institute., Bethesda

  22. PHARMAC (2019) Approval of multi-product funding proposal with Roche. https://www.pharmac.govt.nz/news/notification-2016-12-05-multi-product-proposal/. Accessed 11 September 2020

  23. PHARMAC (2019) Decision to fund oncology, multiple sclerosis and respiratory treatments. https://www.pharmac.govt.nz/news/notification-2019-10-07-various/. Accessed 11 September 2020

Download references

Acknowledgements

We would like to acknowledge the New Zealand Breast Cancer Foundation for the financial support and the Breast Cancer Foundation National Register for providing the detailed data.

Funding

This study was funded by New Zealand Breast Cancer Foundation. The funder did not play any role in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Waikato Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand

    Chunhuan Lao & Ross Lawrenson

  2. Medical Oncology, Waikato District Health Board, Hamilton, New Zealand

    Marion Kuper-Hommel

  3. School of Population Health, The University of Auckland, Auckland, New Zealand

    Mark Elwood

  4. School of Medicine, The University of Auckland, Auckland, New Zealand

    Ian Campbell & Melissa Edwards

  5. General Surgery, Waikato District Health Board, Hamilton, New Zealand

    Ian Campbell

  6. Strategy and Funding, Waikato District Health Board, Hamilton, New Zealand

    Ross Lawrenson

Authors
  1. Chunhuan Lao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marion Kuper-Hommel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Elwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ian Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melissa Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ross Lawrenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data acquisition and analysis were performed by CL. The first draft of the manuscript was written by CL and RL and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chunhuan Lao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lao, C., Kuper-Hommel, M., Elwood, M. et al. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand. Breast Cancer 28, 387–397 (2021). https://doi.org/10.1007/s12282-020-01171-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-020-01171-3

Keywords

Search

Navigation